

Evonik presents nutraceutical innovations at Vitafoods Europe 2024

14 May 2024

- New concept: AvailOm® omega-3 powder & Boswellia for joint health
- New study results: IN VIVO BIOTICS™ synbiotic solutions
- Next Generation Solutions: European-made, evidence-based food ingredients available to food supplement brands

Main press contact

Janusz Berger
Head of Market Communications
Health Care
Phone + 49 6151 18-4984
janusz.berger@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Essen, Germany. Evonik is presenting its latest nutraceutical ingredient innovations at Vitafoods Europe 2024 in Geneva, Switzerland. With the new concept of AvailOm® & Boswellia for joint health, the latest study results on IN VIVO BIOTICS™ and the expansion of the Healthberry® portfolio to the U.S. market, the company provides advanced, evidence-based food ingredients to boost consumer preferences and differentiate functional food and food supplement brands.

The nutraceuticals portfolio at Evonik Health Care includes naturally occurring ingredients with scientifically proven health benefits, as well as nutraceutical coating technologies that help ensure the health ingredients are released in the human body at the right time and location. As part of the life sciences division, Nutrition & Care, Evonik Health Care has centred its business on improving health and quality of life. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution.

"Through our dedication to research and innovation, we provide customized nutra ingredients that address unique health requirements, enabling our partners to offer their customers a convenient and elevated nutritional experience that enhances their quality of life," said Susanne Pluta, Director of Consumer Products at Evonik Health Care.

Key highlights at Vitafoods Europe 2024

- **AvailOm® omega-3 powder and Boswellia serrata ingredient concept.** This unique combination is targeted for

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

joint health applications. Its efficacy and synergistic mechanism have been proven through in-vitro and human intervention studies. The concept combines Evonik's superior formulation expertise and scientific evidence for efficacy.

- **IN VIVO BIOTICS™ concepts:** A recent study showed the superior gluten-degrading efficacy of **IN VIVO BIOTICS™ gluten tolerance**, also in comparison to conventional enzyme-based gluten digestion aids.
- **Expansion of Healthberry® 865/900 to the U.S. market.** With the FDA registration of Evonik's Norwegian facility Medpalett, Healthberry® is now sold in bulk to dietary supplement companies with formulation capabilities and partners in the U.S. for further development and commercialization.

To learn more about Evonik's innovative portfolio of nutraceutical solutions visit **Booth E162** at **Vitafoods Europe 2024**.

Further Information

For all information about Evonik at Vitafoods Europe 2024 see [here](#)

More about:

AvailOm® omega-3

IN VIVO BIOTICS™ synbiotic solutions

Healthberry® anthocyanins

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.